Mar 18, 2023
On Tuesday, the Food and Drug Administration (FDA) announced that it granted an emergency use authorization for Pfizer's bivalent COVID-19 booster in children under 5 years who had previously received three monovalent shots, despite concerns from well-respected doctors about the dangers of the COVID-shots. "Pfizer Inc. and BioNTech SE announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 4 years of age (also referred to as under 5 years of age) at least 2 months after completion of primary vaccination with three doses of the Pfizer-BioNTech COVID-19 Original Vaccine," according to the company's release. "Emergency uses of Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or licensed by FDA but have been authorized by FDA unde